What is the prevalence of jaundice in pregnancy due to cholestasis (intrahepatic cholestasis of pregnancy)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Prevalence of Jaundice in Pregnancy due to Cholestasis

The prevalence of jaundice in pregnancy due to cholestasis, specifically intrahepatic cholestasis of pregnancy (ICP), affects approximately 0.3% to 0.5% of pregnancies.

Key Factors Influencing Prevalence

  • Geography and Ethnicity: The prevalence varies significantly by geography and ethnicity, with higher rates reported in South America, particularly in Chile, and in Sweden and Baltic countries 1.
  • Genetic and Hormonal Factors: Genetic, hormonal (estrogen and sulphated progesterone), and environmental factors have been linked with the risk of developing ICP 1.
  • Maternal Factors: Advanced maternal age, multiparity, metabolic syndrome, and HCV infection are also associated with an increased risk of ICP 1.

Clinical Presentation and Diagnosis

  • Symptoms: The classic symptom of ICP is generalized pruritus, most severe in the palms and soles without an accompanying rash, typically onset in the second or third trimester 1.
  • Laboratory Tests: Elevated serum bile acid levels and AST and ALT levels are common in ICP, with total bile acids >100 μmol/L indicating severe ICP 1.

Fetal Risks

  • Preterm Delivery and Stillbirth: ICP confers risks to the fetus, including preterm delivery, meconium-stained amniotic fluid, and stillbirth, with the prevalence of intrauterine fetal demise (IUFD) increasing with higher serum total bile acid levels 1.

From the Research

Prevalence of Jaundice in Pregnancy due to Cholestasis

  • The prevalence of intrahepatic cholestasis of pregnancy (ICP) varies by region, with higher incidence in South American and Scandinavian countries (9.2%-15.6% and 1.5%, respectively) compared to Europe (0.1%-0.2%) 2.
  • ICP is a rare disorder, predominantly occurring during the third trimester of pregnancy, characterized by pruritus, jaundice, and biochemical disturbances in liver enzymes 3.
  • Jaundice is a common symptom of ICP, occurring in some cases, and is often accompanied by pruritus and elevated serum bile acids concentrations 4, 5.
  • The exact prevalence of jaundice in pregnancy due to cholestasis is not specified in the studies, but it is estimated that ICP accounts for 20% of cases of jaundice occurring in pregnancy 5.

Characteristics of Intrahepatic Cholestasis of Pregnancy

  • ICP is characterized by pruritus, elevated liver enzymes, and increased serum bile acids, typically appearing in the late second or third trimester and resolving after delivery 2, 3, 6.
  • The etiology of ICP is multifactorial, involving genetic, endocrine, and environmental factors 2.
  • Maternal outcome is usually benign, but fetal complications such as preterm labor, meconium staining, fetal distress, and sudden intrauterine fetal demise can occur 2, 3, 6.

Diagnosis and Management of Intrahepatic Cholestasis of Pregnancy

  • Diagnosis of ICP involves careful monitoring of maternal hepatic function tests and serum bile acid levels, as well as assessment of fetal well-being 2, 6.
  • Treatment with ursodeoxycholic acid is suggested, coupled with close maternal-fetal surveillance and delivery as close to term as possible 2, 3, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cholestasis of pregnancy: a review of the evidence.

The Journal of perinatal & neonatal nursing, 2005

Research

Intrahepatic cholestasis of pregnancy: a critical review.

The Journal of perinatal & neonatal nursing, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.